

MDR-TB Data Collection form

Multi-Drug Resistant-Tuberculosis

short-regimen treatment outcome in uMkhanyakude District between 2018 and 2022 An
Epidemiological observational, analytic, retrospective cross-sectional study.

* Indicates required question

1. Email *

2. 1. MDR-TB Institution *

Cohort A "Hlabisa District Hospital" Cohort B "Manguzi district Hospital"

Mark only one oval.

Cohort A Hlabisa District Hospital

Cohort B Manguzi District Hospital

3. 2. MDR-TB Short-regimen Patient *

Mark only one oval.

Yes

No

4. 3. Year Diagnosed with MDR-TB grouping *

Group 1 Patient started treatment in 2018, group 2 patient started treatment in 2019, group 3 patient started treatment in 2020, group 4 patient started treatment in 2021 and group 5 patient started treatment in 2022.

Mark only one oval.

Group 1

Group 2

Group 3

Group 4

Group 5

5. 4. Participant Identification Number *

Cohort/group no./participant no. e.g. B/2/01

Participants Socio-Demographic Information**6. 1. Participant's Sex ***

Mark only one oval.

Male

Female

Transgender

Not-specified

7. 2. Participant's Age *

8. 3. Participant's Home Language *

9. **4. Ethnic Group ***

Mark only one oval.

- Black
- Coloured
- White
- Assian
- Not Specified

10. **5. Marital status ***

Mark only one oval.

- Married
- Divorced
- Single
- Unknown
- Not Specified

11. **6. Education Level ***

Mark only one oval.

- Tertiary
- Collage
- Secondary
- Primary
- No Schooling

12. **7. Occupation ***

Mark only one oval.

- Employed
- Self-employed
- Unemployed
- Not Specified

13. **8. Source of Income ***

Mark only one oval.

- No Income
- Salary/wage
- Pension grant
- Child Support-grant
- Disability grant
- Unemployment Insurance Fund (UIF)

14. **9. Smoking Status ***

Mark only one oval.

- Non-Smoker
- Smoker
- Unknown

15. **10. Family Size ***

16. **11. Mode of transportation to Healthcare Facility ***

Mark only one oval.

- by Bus
- by Car
- by hired car
- by walking
- by Horse
- by Taxi
- Not specified

17. **12. Living Area ***

Mark only one oval.

- Rural
- Urban

Clinical Characteristics of Participants18. **1. Previously Diagnosed with TB? ***

Mark only one oval.

- Yes
- No

19. **2. Previous MDR-TB Treatment ***

Mark only one oval.

- None
- Relapsed
- Interrupted
- Treatment Failure

20. **3. Participant's Weight (Kg) on initiation ***

21. **3. Drug Resistance ***

Mark only one oval.

Yes

No

22. **4. Date of MDR-TB Initiation ***

Example: January 7, 2019

23. **5. Type of drug resistance ***

Mark only one oval.

Isoniazid

Rifampicin

Rifampicin + Isoniazid

Other: _____

24. **6. Comorbidity ***

Mark only one oval.

Present

Absent

25. **7. Comorbid disease ***

Check all that apply.

- Hypertension
- Diabetes Mellitus
- HIV/AIDS
- Chronic obstructive pulmonary disease
- Other: _____

26. **8. Pre-treatment TB Culture baseline ***

Mark only one oval.

- Positive
- Negative
- Unknown

27. **9. Pre-treatment Smear Acid-fast bacilli ***

Mark only one oval.

- Positive
- Negative
- Unknown

28. **10. Radiology ***

Mark only one oval.

- Unilateral
- Bilateral
- Unknown

29. **11. Radiology ***

Mark only one oval.

- Unilateral
- Bilateral
- Unknown value

30. **12. Radiology Cavity ***

Mark only one oval.

- Absent
- Present
- Unknown

31. **13. Duration of Intensive Phase ***

Mark only one oval.

- 4 Months or Less
- 5 - 6 Months
- more than 7 months

32. **14. Duration of Continuation Phase ***

Mark only one oval.

- 4 Months or Less
- 5 - 6 Months
- more than 7 months

33. **15. Smear Microscopy result after 4 months ***

Mark only one oval.

- Positive
- Negative
- No Data documented

34. **16. TB result after 4 months ***

Mark only one oval.

- Positive
- Negative
- No Data documented

35. **17. Treatment Interrupted? ***

Mark only one oval.

- Yes
- No

36. **18. Duration of treatment interruption ***

Mark only one oval.

- For one month
- For two months
- For three months or more
- Not Applicable

37. **19. Adverse Drug Reaction (ADR) Reported ***

Mark only one oval.

Yes

No

Unknown

38. **20. Type of Adverse Drug Reaction (ADR) Reported ***

Check all that apply.

Renal Impairments

Drug Induced Liver Injury

Ototoxic "Hearing loss"

Blindness

No Adverse Drug reaction reported

Other: _____

39. **21. Grading of the Adverse Drug Reaction (ADR) ***

Mark only one oval.

Grade 1 Mild

Grade 2 Moderate

Grade 3 Severe

Grade 4 Life threatening

None of the above

40. **22. MDR-TB Treatment Outcome ***

Mark only one oval.

- Cured
- Completed
- Failed
- Lost to Follow Up
- Died
- Interrupted treatment
- Other: _____

Health facility Assessment41. **1. Patient Provider Communication Language ***

Mark only one oval.

- IsiZulu
- IsiXhosa
- Afrikaans
- English
- Setswana
- SeSotho
- XiTsonga
- SiSwati
- Tshivenda
- IsiNdebele
- Other: _____

42. 2. Facility diagnostic Capacity

Does the facility have or have documented test done for the following

Check all that apply.

- Rapid Drug Susceptibility Testing.
- GeneXpert
- X-ray Images

43. 3. Have the patient experience any of the stock out of MDR-TB medication during the course of treatment ? *

Mark only one oval.

- Yes
- No

44. 4. How many times during the course of treatment did the patient experience stock out of MDR-TB medication *

45. 5. Clinicians attended to the MDR-TB patient during the course of treatment *

Check all that apply.

- Medical Doctor
- Nurse
- Pharmacist
- Audiologist
- Dietician
- Optometrist
- Other: _____

46. **6. Evidence of specially trained and experienced healthcare professionals in managing MDR-TB cases** *

Mark only one oval.

Yes

No

47. **7. Adequate staffing levels to support MDR-TB patients** *

Mark only one oval.

Yes

No

48. **8. Presence of treatment regimen, tracer team and adherence Support:** *

Mark only one oval.

Yes

No

49. **9. Presence of an active Infection Control Measures** *

Mark only one oval.

Yes

No

50. **10. Availability of Patient Educational posters, Flyers and Package insert.** *

Mark only one oval.

Yes

No

This content is neither created nor endorsed by Google.

Google Forms